US FDA alerts patients of potential to miss critical safety alerts due to phone settings when using smartphone-compatible diabetes devices: Maryland Friday, February 7, 2025, 09:0 ...

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

These days, many devices are programmed through apps on patients’ phones. But the FDA warns that certain phone settings, such ...

The US Food and Drug Administration (FDA) is cautioning patients and caregivers about the potential for not receiving blood ...

How does the body regulate the activity of insulin-producing cells in order to react quickly to changing conditions? Researchers have investigated this question.

Patients who use smartphone apps to manage their diabetes could face serious health problems if they miss notifications ...

The hormone insulin plays a central role in the metabolism of many living organisms. When food is plentiful, insulin promotes ...

Health care providers are urged to inform patients to periodically check their smartphone settings and to confirm that they are able to receive alerts.

The Phase 1b/2a study will assess the safety of CNP-103 in adults (aged 18-35) and pediatrics (aged 12-17) who have Stage III or newly diagnosed (within the last 6 months) T1D as well as C-peptide ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Although Mounjaro and insulin have different effects on ... This is the most serious warning from the Food and Drug Administration (FDA). It alerts doctors and patients about drug effects that ...